|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pokorny MR, de Rooij M, Duncan E, Schröder
FH, Parkinson R, Barentsz JO and Thompson LC: Prospective study of
diagnostic accuracy comparing prostate cancer detection by trans
rectal ultrasound-guided biopsy versus magnetic resonance (MR)
imaging with subsequent MR-guided biopsy in men without previous
prostate biopsies. Eur Urol. 66:22–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhang W, Vazquez L, Apperson M and Kennedy
MB: Citron binds to PSD-95 at glutamatergic synapses on inhibitory
neurons in the hippocampus. J Neurosci. 19:96–108. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fujiwara T, Bandi M, Nitta M, Ivanova EV,
Bronson RT and Pellman D: Cytokinesis failure generating
tetraploids promotes tumorigenesis in p53-null cells. Nature.
437:1043–1047. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ganem NJ, Storchova Z and Pellman D:
Tetraploidy, aneuploidy and cancer. Curr Opin Genet Dev.
17:157–162. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
McKenzie C, Bassi ZI, Debski J, Gottardo
M, Callaini G, Dadlez M and D'Avino PP: Cross-regulation between
aurora B and citron kinase controls midbody architecture in
cytokinesis. Open Biol. 6:1600192016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
D'Avino PP and Capalbo L: Regulation of
midbody formation and function by mitotic kinases. Semin Cell Dev
Biol. 53:57–63. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gai M, Camera P, Dema A, Bianchi F, Berto
G, Scarpa E, Germena G and Di Cunto F: Citron kinase controls
abscission through RhoA and anillin. Mol Biol Cell. 22:3768–3778.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yamashiro S, Totsukawa G, Yamakita Y,
Sasaki Y, Madaule P, Ishizaki T, Narumiya S and Matsumura F: Citron
kinase, a Rho-dependent kinase, induces di-phosphorylation of
regulatory light chain of myosin II. Mol Biol Cell. 14:1745–1756.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhao Y and Simon R: BRB-ArrayTools data
archive for human cancer gene expression: A unique and efficient
data sharing resource. Cancer Inform. 6:9–15. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mottet N, Bellmunt J, Bolla M, Briers E,
Cumberbatch MG, De Santis M, Fossati N, Gross T, Henry AM, Joniau
S, et al: EAU-ESTRO-SIOG guidelines on prostate cancer Part 1:
Screening, diagnosis, and local treatment with curative intent. Eur
Urol. 71:618–629. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yu L, Toriseva M, Tuomala M, Seikkula H,
Elo T, Tuomela J, Kallajoki M, Mirtti T, Taimen P, Boström PJ, et
al: Increased expression of fibroblast growth factor 13 in prostate
cancer is associated with shortened time to biochemical recurrence
after radical prostatectomy. Int J Cancer. 139:140–152. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Eble JN, Sauter G, Epstein JE and
Sesterhenn IA: World Health Organization Classification of Tumours.
Pathology and genetics of the urinary system and male genital
organs. IARC Press; Lyon: 2004. pp. 159–215. 2004
|
|
15
|
Epstein JI, Allsbrook WC Jr, Amin MB and
Egevad LL; ISUP Grading Committee, : The 2005 International Society
of Urological Pathology (ISUP) consensus conference on Gleason
grading of prostatic carcinoma. Am J Surg Pathol. 29:1228–1242.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Goktas S, Yilmaz MI, Caglar K, Sonmez A,
Kilic S and Bedir S: Prostate cancer and adiponectin. Urology.
65:1168–1172. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu J, Xiao M, Li J, Wang D, He Y, He J,
Gao F, Mai L, Li Y, Liang Y, et al: Activation of UPR signaling
pathway is associated with the malignant progression and poor
prognosis in prostate cancer. Prostate. 77:274–281. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Roudier MP, Winters BR, Coleman I, Lam HM,
Zhang X, Coleman R, Chéry L, True LD, Higano CS, Montgomery B, et
al: Characterizing the molecular features of ERG-Positive tumors in
primary and castration resistant prostate cancer. Prostate.
76:810–822. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sheng X, Li WB, Wang DL, Chen KH, Cao JJ,
Luo Z, He J, Li MC, Liu WJ and Yu C: YAP is closely correlated with
castration-resistant prostate cancer, and downregulation of YAP
reduces proliferation and induces apoptosis of PC-3 cells. Mol Med
Rep. 12:4867–4876. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Whitworth H, Bhadel S, Ivey M, Conaway M,
Spencer A, Hernan R, Holemon H and Gioeli D: Identification of
kinases regulating prostate cancer cell growth using an RNAi
phenotypic screen. PLoS One. 7:e389502012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Glotzer M: The molecular requirements for
cytokinesis. Science. 307:1735–1739. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Boveri T: Concerning the origin of
malignant tumors by Theodor Boveri. Translated and annotated by
Henry Harris. J Cell Sci. 121:1–84. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Pihan GA, Purohit A, Wallace J, Malhotra
R, Liotta L and Doxsey SJ: Centrosome defects can account for
cellular and genetic changes that characterize prostate cancer
progression. Cancer Res. 61:2212–2219. 2001.PubMed/NCBI
|
|
24
|
Yamamoto Y, Eguchi S, Junpei A, Nagao K,
Sakano S, Furuya T, Oga A, Kawauchi S, Sasaki K and Matsuyama H:
Intercellular centrosome number is correlated with the copy number
of chromosomes in bladder cancer. Cancer Genet Cytogenet.
191:38–42. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bassi ZI, Audusseau M, Riparbelli MG,
Callaini G and D'Avino PP: Citron kinase controls a molecular
network required for midbody formation in cytokinesis. Proc Natl
Acad Sci USA. 110:9782–9787. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Madaule P, Eda M, Watanabe N, Fujisawa K,
Matsuoka T, Bito H, Ishizaki T and Narumiya S: Role of citron
kinase as a target of the small GTPase Rho in cytokinesis. Nature.
394:491–494. 1998. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Madhavan J, Mitra M, Mallikarjuna K,
Pranav O, Srinivasan R, Nagpal A, Venkatesan P and Kumaramanickavel
G: KIF14 and E2F3 mRNA expression in human retinoblastoma and its
phenotype association. Mol Vis. 15:235–240. 2009.PubMed/NCBI
|
|
28
|
Zhang J, Yang PL and Gray NS: Targeting
cancer with small molecule kinase inhibitors. Nat Rev Cancer.
9:28–39. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Garnett MJ and Marais R: Guilty as
charged: B-RAF is a human oncogene. Cancer Cell. 6:313–319. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mossé YP, Laudenslager M, Longo L, Cole
KA, Wood A, Attiyeh EF, Laquaglia MJ, Sennett R, Lynch JE, Perri P,
et al: Identification of ALK as a major familial neuroblastoma
predisposition gene. Nature. 455:930–935. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Grise F, Bidaud A and Moreau V: Rho
GTPases in hepatocellular carcinoma. Biochim Biophys Acta.
1795:137–151. 2009.PubMed/NCBI
|
|
32
|
Tang Y, Olufemi L, Wang MT and Nie D: Role
of Rho GTPases in breast cancer. Front Biosci. 13:759–776. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Fu Y, Huang J, Wang KS, Zhang X and Han
ZG: RNA interference targeting CITRON can significantly inhibit the
proliferation of hepatocellular carcinoma cells. Mol Biol Rep.
38:693–702. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
McKenzie C and D'Avino PP: Investigating
cytokinesis failure as a strategy in cancer therapy. Oncotarget.
7:87323–87341. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Somlyo AV, Bradshaw D, Ramos S, Murphy C,
Myers CE and Somlyo AP: Rho-kinase inhibitor retards migration and
in vivo dissemination of human prostate cancer cells. Biochem
Biophys Res Commun. 269:652–659. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wu Y, He L, Zhang L, Chen J, Yi Z, Zhang
J, Liu M and Pang X: Anacardic acid (6-pentadecylsalicylic acid)
inhibits tumor angiogenesis by targeting Src/FAK/Rho GTPases
signaling pathway. J Pharmacol Exp Ther. 339:403–411. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Porten SP, Whitson JM, Cowan JE,
Cooperberg MR, Shinohara K, Perez N, Greene KL, Meng MV and Carroll
PR: Changes in prostate cancer grade on serial biopsy in men
undergoing active surveillance. J Clin Oncol. 29:2795–800. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sharifi N, Gulley JL and Dahut WL:
Androgen deprivation therapy for prostate cancer. JAMA.
294:238–244. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kirby M, Hirst C and Crawford ED:
Characterising the castration-resistant prostate cancer population:
A systematic review. Int J Clin Pract. 65:1180–1192. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Puhr M, Hoefer J, Eigentler A, Ploner C,
Handle F, Schaefer G, Kroon J, Leo A, Heidegger I, Eder I, et al:
The Glucocorticoid receptor is a key player for prostate cancer
cell survival and a target for improved Antiandrogen therapy. Clin
Cancer Res. 24:927–938. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Arora VK, Schenkein E, Murali R, Subudhi
SK, Wongvipat J, Balbas MD, Shah N, Cai L, Efstathiou E, Logothetis
C, et al: Glucocorticoid receptor confers resistance to
antiandrogens by bypassing androgen receptor blockade. Cell.
155:1309–1322. 2013. View Article : Google Scholar : PubMed/NCBI
|
